By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on Viking Therapeutics (VKTX), citing significant execution risk and competition in the GLP-1/GIP space, with Phase 3 results not expected until 2027-2028. The key risk is the long timeline and binary nature of the trials, while the key opportunity is the potential for a dual-formulation strategy to improve tolerability and create a maintenance niche.
Risk: Long timeline and binary nature of Phase 3 trials
Opportunity: Potential for a dual-formulation strategy to improve tolerability
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Viking Therapeutics (NASDAQ: VKTX) stock rose by 19.2% in June, according to data from S&P Global Market Intelligence. The move comes as optimism rises over the company's pipeline development program, notably in weight-loss drugs, and the initiation of a Phase 1 study in a new class of weight-loss drugs that offers a different mechanism from the current GLP-1/GIP class.
Speaking of GLP-1/GIP class drugs, Viking's lead drug candidate, VK2735, is a GLP-1/GIP agonist. It's part of a crowded field that includes blockbuster weight loss drugs from Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
That said, VK2735 does have some distinguishing characteristics that mark it out from rivals. As previously discussed, VK2735 has demonstrated a steeper rate of weight loss in the treated groups in Phase 2 clinical trials for both oral and injectable formulations. The hope is that Viking will demonstrate similar efficacy with no safety or tolerability issues in the ongoing Phase 3 trial for injectable VK2735, as well as in the Phase 3 trial for oral VK2735, which is due to start later this year. Investors will probably have to wait until 2027 and 2028, respectively, for the results of those trials.
The second major plus about VK2735 is that it's being developed as a dual-formulation therapy, with the potential for an initial injectable dose to achieve rapid weight loss, followed by an orally administered maintenance dose. In fact, Viking has an ongoing Phase 1 maintenance trial with initial results (for the 19-week injectable dose) due in the third quarter, followed by results for the oral maintenance dose, set for early 2027.
Investor optimism over these trials grew in June.
In addition, the company announced the initiation of a Phase 1 study of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). It represents a new class of drug with a different mechanism, and the trial is proof positive that Viking has more in its arsenal of weight-loss drugs than VK2735.
History is littered with pharmaceutical companies that rode a wave of optimism only to disappoint investors, and that may happen again with Viking. That said, VK2735 clearly has a lot of potential, not least as an efficacious dual-formulation strategy, and if Phase 1 maintenance trial results are positive, investors will be more willing to price that potential in. Something for investors to hope for in 2026.
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $418,761! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,195,804!
Now, it’s worth noting Stock Advisor’s total average return is 918% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of July 3, 2026. *
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Multi-year timelines to Phase 3 data plus established competitors make the VKTX rally fragile absent flawless near-term readouts."
The article frames VKTX's 19% June gain as driven by VK2735's steeper Phase 2 weight-loss curves and its dual injectable-to-oral maintenance plan, plus the new VK3019 DACRA entering Phase 1. Yet pivotal Phase 3 readouts sit in 2027-2028, leaving years of binary risk in a field already led by LLY's tirzepatide and NVO's semaglutide. The maintenance trial's Q3 injectable data is the only near-term catalyst; any tolerability miss could erase the premium. Crowded GLP-1 space plus typical biotech dilution risk are downplayed.
Positive Q3 maintenance data could still trigger another re-rating even if full approval is distant, given obesity TAM size and precedent of early signals lifting peers like Structure Therapeutics.
"Viking's current market cap reflects an unrealistic expectation of flawless Phase 3 execution and ignores the insurmountable commercial scale advantage held by established GLP-1 incumbents."
Viking Therapeutics is currently priced as a binary outcome play. While the 19.2% June surge reflects excitement over the VK2735 dual-formulation strategy, investors are ignoring the massive capital expenditure and execution risk inherent in scaling Phase 3 trials against incumbents like Eli Lilly and Novo Nordisk. These giants have already secured massive manufacturing capacity and deep-pocketed commercial distribution networks. Viking’s 'best-in-class' efficacy claims in early trials don't guarantee market share if they cannot solve the supply chain bottleneck or if the FDA demands more stringent long-term cardiovascular safety data. At this valuation, the market is pricing in near-perfect clinical execution, leaving zero margin for error in upcoming trial readouts.
If Viking’s oral formulation proves significantly more tolerable than current injectables, they could disrupt the entire obesity market by capturing the massive 'maintenance' patient segment that prefers avoiding needles.
"VKTX's valuation assumes clinical superiority will translate to market share and pricing power in a sector rapidly commoditizing toward generic/biosimilar parity by 2028–2030."
VKTX's 19.2% June surge rests on three pillars: Phase 2 efficacy data for VK2735, a dual-formulation strategy (injectable + oral), and pipeline diversification via VK3019. The article cites steeper weight loss versus competitors (LLY, NVO) but provides zero numbers—'steeper' is marketing language, not data. Phase 3 results won't arrive until 2027–2028, meaning 18–24 months of pure sentiment. The real risk: GLP-1/GIP is commoditizing fast. Novo's Ozempic/Wegovy face generic/biosimilar pressure by 2028. Even if VK2735 shows 5–10% superior efficacy, that's clinically marginal and won't justify a valuation premium in a crowded, price-competitive market. The article ignores manufacturing scale, payer coverage, and the fact that 'better' doesn't equal 'profitable.'
If VK2735 demonstrates both superior efficacy AND better tolerability (fewer GI side effects, for instance), the dual-formulation model could genuinely differentiate in a market where patient dropout is high; early Phase 1 maintenance data in Q3 2026 could re-rate the stock 40–60% if positive.
"VKTX’s rally appears to be price‑in incremental upside that hinges on long, uncertain Phase 3 outcomes; without clear, superior Phase 3 data, the risk/reward looks skewed to the downside."
The June rally in VKTX looks like hype around a dual‑formulation weight‑loss program and a broader pipeline (VK2735 plus VK3019). Yet the core risk is execution and timing: Phase 3 readouts aren’t due until 2027–2028, and even with Phase 2 signals, real‑world safety, tolerability, and payer/reimbursement hurdles could cap upside. The weight‑loss space is highly competitive (Lilly/Novo), and a late or messy Phase 3 could wipe out speculative gains. The article’s bullish framing glosses cash/runway, potential dilution, and the risk that pivotal data disappoints.
Strong Phase 3 results with solid safety could justify a re-rating toward GLP-1 peers despite the long horizon. If data don’t materialize or safety issues arise, the hype could unwind quickly and the stock could sharply underperform.
"Oral formulation's tolerability edge could unlock partnerships years before Phase 3, blunting dilution and scale risks."
Claude underplays how VK2735's oral option could cut GI dropouts that currently exceed 30% for injectables, creating a durable maintenance niche before 2027 Phase 3 data. This directly mitigates Gemini's manufacturing bottleneck concern by shrinking required scale. If Q3 tolerability holds, early partnership talks with LLY or NVO become plausible, offsetting dilution risk the group treats as inevitable.
"Partnership speculation fails to account for the high cost of Phase 3 trials and the lack of urgency from incumbents to pay a premium for unproven assets."
Grok, your reliance on partnership speculation as a hedge against dilution is dangerous. Big Pharma won't overpay for an asset that still requires expensive, multi-year Phase 3 trials to prove non-inferiority in safety. If the Q3 data is strong, Viking is more likely to be squeezed by incumbents waiting for the stock to crater during the long, cash-burning clinical slog. You are betting on an M&A exit that ignores the current regulatory climate for obesity drug pricing.
"Partnership odds hinge on whether Q3 shows superiority or mere parity in tolerability—Grok assumes the former without evidence."
Gemini's M&A skepticism is sound, but misses a critical detail: Viking doesn't need Big Pharma's overpayment—they need a commercial co-development deal post-Phase 2b, not an acquisition. Lilly and Novo routinely license late-stage assets at risk-adjusted valuations. The real question Grok dodges: does Q3 maintenance data actually prove oral tolerability superiority, or just non-inferiority? If it's the latter, the partnership thesis collapses and dilution becomes unavoidable.
"Oral tolerability must translate into real partnerships and value, not just an early maintenance hype, to justify current valuation."
Grok's claim that introducing an oral VK2735 would slash GI dropouts and sidestep manufacturing bottlenecks feels speculative. Even with better tolerability, scale-up, supply agreements, and payer pricing remain gating factors, and a durable maintenance niche may still hinge on Phase 3 success years away. The real determinant for 2026–27 is whether Q3 data show a true tolerability edge that unlocks risk-sharing partnerships, not just hope for an early maintenance narrative.
The panel consensus is bearish on Viking Therapeutics (VKTX), citing significant execution risk and competition in the GLP-1/GIP space, with Phase 3 results not expected until 2027-2028. The key risk is the long timeline and binary nature of the trials, while the key opportunity is the potential for a dual-formulation strategy to improve tolerability and create a maintenance niche.
Potential for a dual-formulation strategy to improve tolerability
Long timeline and binary nature of Phase 3 trials